Saligren capsules are a medication specifically designed to combat oral dryness, containing 30 mg of cevimeline hydrochloride hydrate, a potent parasympathomimetic and muscarinic agonist. The active ingredient, cevimeline hydrochloride, exerts its therapeutic effects by selectively targeting and activating M1 and M3 receptors of the parasympathetic nervous system.
Upon ingestion, the cevimeline in Saligren capsules rapidly interacts with the M1 and M3 receptors present in the salivary glands and other tissues within the oral cavity. By doing so, it initiates a cascade of intracellular events that lead to an increased secretion of saliva. The activation of these receptors stimulates the acinar cells of the salivary glands, encouraging the production and release of saliva into the mouth.
Through its muscarinic agonist properties, cevimeline hydrochloride not only enhances salivary flow but also alleviates the symptoms associated with oral dryness. As a result, patients experience relief from the discomfort of dry mouth and the difficulties in speaking, chewing, and swallowing, often caused by conditions like Sjogren's syndrome or psychosomatic oral disease.
Extensive clinical studies have corroborated the efficacy of Saligren capsules in treating oral dryness. Over a 52-week period, patients with Sjogren's syndrome were administered 30 mg capsules of cevimeline hydrochloride, which led to a significant increase in salivary flow rates. Additionally, both subjective and objective symptoms related to oral dryness showed marked improvement.
Apart from its successful application in Sjogren's syndrome, cevimeline hydrochloride is currently being utilized to effectively manage dry mouth in patients with psychosomatic oral disease. This application highlights the versatility of the drug in addressing different underlying causes of oral dryness, making it a valuable therapeutic option for a wide range of patients.
Active principles: cevimeline hydrochloride hydrate
Amount: 84 capsules
Maker: Nippon Kayaku Co., Ltd., Tokyo, Japan
Indications: treatment of dry mouth in the patients with Sjogren's syndrome
Adults should take 1 capsule (30 mg of the active principle) 3 times a day after meals.
Contraindications: do not use for the following patients:
As this medicine may cause miosis, patients should take care when driving a car during the evening, or operating dangerous machinery in a dark place.
If an allergic reaction occurs, patient needs to stop using the medicine and consult with their doctor. If patient is taking any other medication or treatment, they should consult with their doctor in advance.
